A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 222 participants.
Also called NCT07222917
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 222 participants
- Sponsor
- Registry
-
NCT07222917
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Bulgaria, Canada, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT07222917. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-05 (actual); primary completion 2026-12-10 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
- Acronym
- BaxDuo-Baltic
- Condition
- Chronic Kidney Disease and Hypertension
- Intervention (Drug)
- Baxdrostat/dapagliflozin
- Intervention (Drug)
- Baxdrostat/Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07222917- Content hash
5663bae52b82c87a733bd0c06adeca0b1db7a2aab11a071465a91a89fba5f8af